Tejas Savant
Stock Analyst at Morgan Stanley
(3.22)
# 1,111
Out of 5,113 analysts
250
Total ratings
48.94%
Success rate
1.4%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $40 → $48 | $38.48 | +24.74% | 15 | Dec 2, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $580.46 | +15.43% | 16 | Dec 2, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $80 → $85 | $63.65 | +33.54% | 6 | Dec 2, 2025 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $24 | $16.02 | +49.81% | 3 | Dec 2, 2025 | |
| PSNL Personalis | Maintains: Equal-Weight | $9 → $11 | $9.68 | +13.64% | 14 | Dec 2, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $265 | $234.00 | +13.25% | 15 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $239.60 | +10.60% | 12 | Dec 2, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $85 → $110 | $99.52 | +10.53% | 3 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $20.71 | -3.43% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $75.09 | +1.21% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $18.00 | -11.11% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $149.28 | -29.66% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $10.85 | +10.60% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $12.38 | -35.38% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $5.08 | +37.80% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $9.50 | -26.32% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.42 | +46.20% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $5.62 | +273.67% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $2.34 | -14.53% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $9.34 | +328.27% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.06 | +191.26% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $5.25 | +90.48% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $4.70 | -41.49% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.93 | +416.85% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $108.67 | -32.82% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $217.73 | +14.82% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $10.33 | +868.05% | 5 | May 12, 2022 |
Veracyte
Dec 2, 2025
Maintains: Underweight
Price Target: $40 → $48
Current: $38.48
Upside: +24.74%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $580.46
Upside: +15.43%
Tempus AI
Dec 2, 2025
Maintains: Overweight
Price Target: $80 → $85
Current: $63.65
Upside: +33.54%
Stevanato Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $24
Current: $16.02
Upside: +49.81%
Personalis
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $9.68
Upside: +13.64%
Natera
Dec 2, 2025
Maintains: Overweight
Price Target: $220 → $265
Current: $234.00
Upside: +13.25%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $239.60
Upside: +10.60%
GRAIL
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $85 → $110
Current: $99.52
Upside: +10.53%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $20.71
Upside: -3.43%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $75.09
Upside: +1.21%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $18.00
Upside: -11.11%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $149.28
Upside: -29.66%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $10.85
Upside: +10.60%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $12.38
Upside: -35.38%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $5.08
Upside: +37.80%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $9.50
Upside: -26.32%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.42
Upside: +46.20%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $5.62
Upside: +273.67%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $2.34
Upside: -14.53%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $9.34
Upside: +328.27%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.06
Upside: +191.26%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $5.25
Upside: +90.48%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $4.70
Upside: -41.49%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.93
Upside: +416.85%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $108.67
Upside: -32.82%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $217.73
Upside: +14.82%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $10.33
Upside: +868.05%